Jagsonpal Pharmaceuticals Ltd — earnings calls
2 quarters summarised from transcripts filed with the exchange, every statement cited. Newest first.
Jagsonpal Pharmaceuticals reported Q1 FY27 revenue growth of about 9% year-on-year to Rs.82 crores, with operating EBITDA up around 21% to close to Rs.19 crores and PAT up 22% to Rs.13 crores. The company completed an 85% stake acquisition in Aequitas Healthcare for Rs.20.8 crores, giving it entry into the hospital pharmaceutical segment, and also completed a Rs.40 crores share buyback during the quarter. Management described organic growth initiatives around brand-building, productivity improvement, and portfolio shift toward semi-chronic and specialty therapies.
Jagsonpal reported a Q4 FY26 recovery with revenue up 10% year-on-year to Rs 64 crore and EBITDA up 9% to close to Rs 11 crore, while full-year FY26 revenue grew about 7% to Rs 287 crore. Management attributed the quarter's acceleration to improved MR productivity, field force retention, and outperformance versus the Indian Pharma Market. The board also announced a Rs 40 crore buyback at Rs 250 per share and a 200% dividend including a one-time special dividend of 75%.